BIOCON LIMITED Patent applications |
Patent application number | Title | Published |
20160003826 | PROCESS FOR DETECTION AND OPTIONAL QUANTIFICATION OF AN ANALYTE - The present disclosure relates to a process for detecting and optionally quantifying an analyte in a sample in the presence of a soluble target of the analyte. The soluble target forms a complex with the analyte and thus may interfere in determining the total analyte concentration. The process of the present invention utilizes a unique modified citrate buffer for diluting the sample containing the analyte and the soluble target which in turn helps in dissociating the analyte-soluble target complex, thereby enabling the process of the disclosure to detect and optionally quantify measure the analyte accurately. | 01-07-2016 |
20150118710 | SECRETION OF FUNCTIONAL INSULIN GLARGINE DIRECTLY INTO THE CULTURE MEDIUM THROUGH OVER EXPRESSION OF KEX2P INTRACELLULARLY - The disclosure relates to a process of obtaining a fully folded two chain insulin glargine that require no further processing to make it functionally active. The present disclosure discloses a surprising effect of over expression of Kex2p intracellularly under the control of inducible FLD1 promoter in the host | 04-30-2015 |
20140275535 | ACID ADDITION SALTS OF BOSENTAN - The present invention relates to the stable acid addition salts of Bosentan that are useful for the purification of Bosentan base. In particular, the Bosentan acid addition salt is selected from Bosentan citrate and Bosentan tartrate. | 09-18-2014 |
20140141467 | Fermentation Medias and Processes Thereof - The present invention demonstrates the utility of carbonic acid amides such as urea or its derivatives, carbamates, carbodiimides & thiocarbamides as nitrogenous supplements in fermentation media for production of recombinant proteins to achieve enhanced bioconversion rates and peptides like insulin and insulin analogues, exendin and enzymes such as lipase using methanol inducible fungal expression systems such as | 05-22-2014 |
20140031529 | MONOCLONAL ANTIBODY AND A METHOD THEREOF - The present invention relates to a humanized IgG1 isotype anti-CD6 antibody (T1h) that binds to the Scavenger receptor cysteine-rich (SRCR) domain 1 (D1) of CD6 present on the surface of thymic epithelial cells, monocytes, activated T cells and a variety of other cells types. | 01-30-2014 |
20140005355 | PROCESS FOR PREPARATION OF CASPOFUNGIN ACETATE AND INTERMEDIATES | 01-02-2014 |
20130287802 | TARGETED/IMMUNOMODULATORY FUSION PROTEINS AND METHODS FOR MAKING SAME - The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance of cancer cells. | 10-31-2013 |
20120309935 | METHOD OF REDUCING GLYCOSYLATION OF PROTEINS, PROCESSES AND PROTEINS THEREOF - The disclosure relates to method of reducing O-glycosylation levels of the insulin or insulin analog precursor molecule produced by | 12-06-2012 |
20120231520 | NOVEL FUSION PROTEINS AND METHOD OF EXPRESSION THEREOF - The present invention relates to novel Prolipase-Bovine trypsinogen (PLBTR) fusion proteins, the genes encoding them, and the production and uses thereof. More specifically, the present invention relates to methods of producing in optimal quantities PLBTR fusion proteins which comprise a heterologous polypeptide which is normally susceptible to autocatalytic activity. More particularly, the present invention relates to fusion proteins which comprise an heterologous polypeptide, such as a serine protease, fused to a lipase signal sequence, which can be expressed by recombinant host cells in desired amounts. The present invention further relates to polynucleotides encoding such fusion proteins, to expression vectors for expression of such fusion proteins, to host cells transformed with such polynucleotides/vectors, and to methods of generating such fusion proteins. | 09-13-2012 |
20120178900 | CHROMATOGRAPHIC PROCESSES AND PURIFIED COMPOUNDS THEREOF - The present disclosure demonstrates the utility of ion pairing agents in the preparative scale of purification. More particularly, the disclosure relates to the usage of ion pairing agents in RP preparative linear chromatography enabling high purity of the desired end product. The disclosure shows that ion-pairing agents have dramatic effect on desired purity of polypeptides. | 07-12-2012 |
20120123089 | PREPARATIVE NON-LINEAR GRADIENT BASED CHROMATOGRAPHIC METHOD AND PURIFIED PRODUCTS THEREOF - The instant disclosure provides a method for purification of peptides by chromatographic techniques. The proposed methodology will help in addressing the problems associated in purifying biological protein products emerging from the evolving biotechnology industry. | 05-17-2012 |
20110245285 | PROCESS FOR PREPARATION OF ROSUVASTATIN ACETONIDE CALCIUM - The present invention is in relation to a process for preparation of HMG-CoA reductase inhibitor. More particularly, the present invention provides a process for preparation of (3R,5S,6E) 6-{2-[4-(4-Fluoro-phenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-vinyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid, calcium salt (Rosuvastatin acetonide calcium) which is used for treating hypercholesterolemia. | 10-06-2011 |
20110236925 | Method of Obtaining a Purified, Biologically Active Heterologous Protein - The invention relates to methods of separation and/or purification of impurities yielding a purified heterologous protein product devoid of related impurities or with substantially minimal quantities of such glycosylated impurities. More specifically, the invention relates to the identification of glycosylated forms of insulin analogues such as glargine impurities characterized post expression in yeast based systems such as | 09-29-2011 |
20110159538 | Process for Preparation of Insulin Compounds - The present invention relates to the preparation of insulin compounds including their analogs or derivatives thereof from their corresponding precursor forms by a one step enzymatic reaction involving the combinatorial and concurrent use of optimal quantities of trypsin and carboxypeptidase B that work synergistically directing the reaction in a controlled manner to avoid production of random undesired byproducts. Particularly, the enzymatic conversion reactions of the instant invention offer advantages of reduction in the number operational steps, higher yield and purity of the desired end products. | 06-30-2011 |
20110118480 | METHOD OF SYNTHESIZING A SUBSTANTIALLY MONODISPERSED MIXTURE OF OLIGOMERS - The present invention relates to methods of synthesizing oligomeric compounds, and more particularly, to methods of synthesizing oligomer compounds comprising polyethylene glycol moieties. The present invention provides improved methods for synthesizing oligomers comprising polyethylene glycol moieties. Methods according to embodiments of the present invention may utilize reaction conditions that are milder, efficacious than those taught by conventional methods. | 05-19-2011 |
20100317827 | Method of Purifying a Peptide - The invention relates, interalia, to the field of purification of peptides, notably cyclic or non-cyclic peptides their analogs or derivatives thereof. More particularly, the invention relates to a simplified and optimized purification process of cyclic peptides from a composition comprising the said peptide and at least one related impurity by chromatographic procedures enabling high yields, selectivity and purity of the desired end product. The improved process is particularly useful for the preparation of eptifibatide, exenatide, atosiban, nesiritide and their respective derivatives and analogs. The polypeptides are prepared in high purity of at least about 96%, and preferably at least about 99%. | 12-16-2010 |
20100317056 | FERMENTATION MEDIAS AND PROCESSES THEREOF - The present invention demonstrates the utility of carbonic acid amides such as urea or its derivatives, carbamates, carbodiimides & thiocarbamides as nitrogenous supplements in fermentation media for production of recombinant proteins to achieve enhanced bioconversion rates and peptides like insulin and insulin analogues, exendin and enzymes such as lipase using methanol inducible fungal expression systems such as | 12-16-2010 |
20100285143 | ORALLY ADMINISTERABLE SOLID PHARMACEUTICAL COMPOSITION AND A PROCESS THEREOF - The invention relates to improvised pharmaceutical compositions permitting ingestion via oral delivery of proteins/peptides or their conjugates, and/or cation-insulin conjugate complexes demonstrating desirable pharmacokinetic profiles and potency in efficacy models of diabetes in dogs and humans. A preferred formulation comprises 0.01%-20% w/w of insulin, insulin compound conjugates and/or cation insulin conjugates, 10%-60% w/w of one or more fatty acid components selected from saturated or unsaturated C4-C12 fatty acids and/or salts of such fatty acids and additionally contains optimal amounts of other pharmaceutically suitable polymer excipients which permit improved solubility, dissolution rate and effective bioavailability of poorly water soluble compositions and consistent in-vivo release profiles upon scalability during manufacture. A further aspect of the invention features the process of preparing the aforesaid formulations. | 11-11-2010 |
20100167342 | METHOD OF PRODUCING BIOLOGICALLY ACTIVE POLYPEPTIDE HAVING INSULINOTROPIC ACTIVITY - The present invention relates to a method of producing a biologically active polypeptide having insulinotropic activity, the method comprising steps of: (a) transforming a genetically modified host cell that has protease gene knockout, with a polynucleotide vector encoding the polypeptide; and (b) growing the transformed host cell to produce the biologically active polypeptide; and a method of producing a biologically active polypeptide having an N-terminal recognition site His-Gly with insulinotropic activity, the method comprising steps of: (a) transforming a genetically modified | 07-01-2010 |
20100029933 | PURE FORM OF RAPAMYCIN AND A PROCESS FOR RECOVERY AND PURIFICATION THEREOF - The present invention relates to a pure form of rapamycin with a total impurity content less than 1.2%; a process for recovery and purification of rapamycin comprising steps of (a) treating the fermentation broth, extracts or solutions containing rapamycin with water immiscible solvent and concentration; (b) addition of a water miscible solvent to effect separation of impurities present; (c) optionally, binding of the solvent containing the product from step (b) to an inert solid, washing the solid with a base and acid, followed by elution; (d) subjecting the elute from step (c) or the solvent containing the product from step (b) to silica gel chromatography; (e) crystallization of the product obtained from step (d); (f) subjecting a solution of the product from step (e) to hydrophobic interaction or reversed phase chromatography; and (g) re-crystallization to afford rapamycin in substantially pure form. | 02-04-2010 |
20090171099 | PROCESS FOR THE PRODUCTION OF AMORPHOUS ATORVASTATIN CALCIUM - A novel process of the preparation of amorphous atorvastatin calcium starting from a compound of Formula (II). | 07-02-2009 |
20090082421 | Crystalline Form B4 of Atorvastatin Magnesium and a Process Thereof - Crystalline polymorphic form B4 of Atorvastatin magnesium of FIG. | 03-26-2009 |
20080286842 | Process for the Production of Macrolides Using a Novel Strain, Streptomyces Sp. Bicc 7522 - The present invention discloses a new strain of | 11-20-2008 |